by Raynovich Rod | Dec 24, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Rayno Life Science Stock Picks Beat The Market Everybody now knows about the bull market in biotech stocks. Innovative products, favorable clinical news, M&A (see below) and breakthrough genomic technologies and targeted therapies have driven most life science...
by Raynovich Rod | Dec 20, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Santa Claus Making Fast Tracks Nasdaq is up 1% as of midday trading and life science stocks are strong across the board. The IBB is up 2.29%, XBI up 1.8 %.The holiday spirit pervades. Movers among the Rayno Life Science focus stocks are the usual suspects plus many...
by Raynovich Rod | Dec 16, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
But A Lot of Green Today in Diagnostics and Tools The NASDAQ (4030)and the S&P (1787) are up about 0.7% but biotech stocks are lagging with the IBB ($216) up only 0.33%. Momentum in biopharmaceutical stocks has been easing since a late November move around the...
by Raynovich Rod | Dec 9, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Weak Tape Today 12/10–Gilead (GILD) Down 4.4% on 15.5M Shares IBB ($218.81) down 1.33% on good volume. GILD fall could be reaction to Abbvie (ABBV $53.55) up 4.5% on Phase 3 Hepatitis C data. Virologic response of ABT-450r is 96% in Genotype 1 patients. Other...
by Raynovich Rod | Nov 21, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
NanoString Technologies (NSTG $12) is an early stage, life science research Company with a proprietary platform product, the nCounter (R) Analysis System. The nCounter utilizes a proprietary bar code chemistry and technology that can multiplex hundreds of gene...
by Raynovich Rod | Nov 21, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Another Strong Day in Life Science Stocks Carl Icahn, activist investor takes a 13% stake in Hologic. Hologic (HOLX $22.82) was added to our portfolio on 4/9/13 but has been a laggard due to earnings misses. The stock is up 2.4% on a volume of 25M shares. Many stocks...
by Raynovich Rod | Nov 14, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Rayno Diagnostics and Tools Focus Stocks: 2013 Performance YTD A diversified life science portfolio must include clinical diagnostics and tools stocks because the synergies between therapy and diagnostics have never been stronger. Breakthroughs in molecular...
by Raynovich Rod | Nov 6, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Strong Jobs Report Boosts Market–Treasuries Sell -Off with 10 Year up to 2.74% Volatile Week Finds Buyers-Technical Levels Hold 11/8/13 9:45 a Biotechnology stocks rebounded today with the IBB up 3% to $203.86. The sector hit a major downdraft yesterday but we...
by Raynovich Rod | Nov 1, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Equities: The Only Game in Town With Rates Under 3%? October, normally a month to be cautious on the market, proved that trends can be misleading even in the midst of turbulent times in Washington. DOW Up 2.5%, S&P Up 3.5%, NASDAQ Up 2.5%. Healthcare stocks...
by Raynovich Rod | Oct 29, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Dow, S&P and Biotech Sector Hit All Time Highs NASDAQ Still 1000+Pts Under 2000 High Levels After a 10% sell-off in early October many large cap biopharmaceutical and diagnostic stocks are at new highs with the major indices at or near their October highs. The...
